This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Amicus Therapeutics Announces Full-Year 2012 Financial Results And Corporate Updates

Forward-Looking Statements

This press release contains, and the accompanying conference call will contain, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, and the projected cash position for the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "potential," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Table 1           
Amicus Therapeutics, Inc.
(a development stage company)
Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
           
          Period from
          February 4, 2002
          (inception)
  Three Months Twelve Months To
  Ended December 31, Ended December 31, Dec. 31,
  2011 2012 2011 2012 2012
Revenue:          
Research revenue $3,970 $ -- $14,794 $11,591 $57,493
 Collaboration and milestone revenue 1,660 -- 6,640 6,820 64,382
Total revenue 5,630  -- 21,434 18,411 121,875
           
Operating Expenses:          
Research and development 14,401 11,047 50,856 50,273 315,893
General and administrative 3,917 4,455 19,880 19,364 132,613
Restructuring charges -- -- -- -- 1,522
Impairment of leasehold improvements -- -- -- -- 1,030
Depreciation and amortization 342 421 1,585 1,705 11,768
In-process research and development -- -- -- -- 418
Total operating expenses 18,660 15,923 72,321 71,342 463,244
Loss from operations (13,030) (15,923) (50,887) (52,931) (341,369)
Other income (expenses):          
Interest income 24 81 160 316 14,389
Interest expense (27) (12) (148) (89) (2,422)
Change in fair value of warrant liability  742 2,594 2,764 653 1,553
Other income -- -- 70 21 252
Loss before tax benefit (12,291) (13,260) (48,041) (52,030) (327,597)
Benefit from income taxes 3,629 3,245 3,629 3,245 8,708
Net loss (8,662) (10,015) (44,412) (48,785) (318,889)
Deemed dividend -- -- -- -- (19,424)
Preferred stock accretion -- -- -- -- (802)
Net loss attributable to common stockholders $(8,662) $(10,015) $(44,412) $(48,785) $(339,115)
Net loss attributable to common stockholders per common share – basic and diluted $(0.25) $(0.20) $(1.28) $(1.07)  
Weighted-average common shares outstanding – basic and diluted 34,643,722 49,477,596 34,569,642 45,565,217  
           

 

Table 2
Amicus Therapeutics, Inc.
(a development stage company)
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
     
  December 31, December 31,
  2011 2012
Assets:    
Current assets:    
Cash and cash equivalents $ 25,668 $ 33,971
Investments in marketable securities 30,034 65,151
Receivable due from GSK 5,043 3,225
Prepaid expenses and other current assets 5,903 2,270
Total current assets 66,648 104,617
     
Property and equipment, less accumulated depreciation and amortization of $9,507 and $8,501 at December 31, 2011 and 2012, respectively 2,438 5,029
Other non-current assets 709 442
Total Assets $ 69,795 $ 110,088
     
Liabilities and Stockholders' Equity    
Current liabilities:    
Accounts payable and accrued expenses $ 9,708 $ 8,845
Current portion of deferred reimbursements 8,504 --
Current portion of secured loan 1,044 398
Total current liabilities 19,256 9,243
     
Deferred reimbursements, less current portion 18,999 30,418
Warrant liability 1,948 908
Secured loan, less current portion -- 299
     
Commitments and contingencies    
     
Stockholders' equity:    
Common stock, $.01 par value, 125,000,000 shares authorized, 34,654,206 shares issued and outstanding at December 31, 2011,49,631,672 shares issued and outstanding at December 31, 2012 407 556
Additional paid-in capital 299,285 387,539
Accumulated other comprehensive income 4 14
Deficit accumulated during the development stage (270,104) (318,889)
Total stockholders' equity 29,592 69,220
Total Liabilities and Stockholders' Equity $ 69,795 $ 110,088

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044

Stock quotes in this article: FOLD 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs